Therapeutic options for ampullary carcinomas. A review

IF 3.1 Q2 ONCOLOGY

Oncology Reviews Pub Date : 2019-07-22 DOI:10.4081/oncol.2019.440

Dileep Kumar Reddy Regalla, R. Jacob, A. Manne, R. Paluri

{"title":"Therapeutic options for ampullary carcinomas. A review","authors":"Dileep Kumar Reddy Regalla, R. Jacob, A. Manne, R. Paluri","doi":"10.4081/oncol.2019.440","DOIUrl":null,"url":null,"abstract":"Ampullary Carcinoma arises from a histologically heterogeneous region where three different epithelia converge. Even though Ampullary Carcinoma has a superior prognosis compared to pancreatic and biliary ductal neoplasms, at least half of the patients turn up at an advanced stage that limits the treatment prospects. In addition to surgery for early-stage disease, several studies have shown that chemoradiotherapy confers additional benefits in the management of Ampullary Carcinoma. Analogously, chemotherapy plays a crucial role in treating advanced Ampullary Carcinoma with distant metastasis/recurrences. Although, stage of the disease, lymph node status, and histo-morphology are three critical prognostic variables, recently much attention is being placed on the genetic landscape of Ampullary Carcinoma. In this review, we have discussed various studies describing the role of chemoradiation and chemotherapy in the treatment of early and advanced stage Ampullary Carcinoma. Also, we have summarized the molecular landscape of Ampullary Carcinoma and the novel therapeutic strategies which could possibly target the genetic alterations involving the tumor cells.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.440","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2019.440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 13

Abstract

Ampullary Carcinoma arises from a histologically heterogeneous region where three different epithelia converge. Even though Ampullary Carcinoma has a superior prognosis compared to pancreatic and biliary ductal neoplasms, at least half of the patients turn up at an advanced stage that limits the treatment prospects. In addition to surgery for early-stage disease, several studies have shown that chemoradiotherapy confers additional benefits in the management of Ampullary Carcinoma. Analogously, chemotherapy plays a crucial role in treating advanced Ampullary Carcinoma with distant metastasis/recurrences. Although, stage of the disease, lymph node status, and histo-morphology are three critical prognostic variables, recently much attention is being placed on the genetic landscape of Ampullary Carcinoma. In this review, we have discussed various studies describing the role of chemoradiation and chemotherapy in the treatment of early and advanced stage Ampullary Carcinoma. Also, we have summarized the molecular landscape of Ampullary Carcinoma and the novel therapeutic strategies which could possibly target the genetic alterations involving the tumor cells.

查看原文本刊更多论文

壶腹癌的治疗选择。回顾

壶腹癌起源于三个不同上皮细胞汇聚的组织学异质区域。尽管与胰腺和胆管肿瘤相比，壶腹癌的预后更好，但至少有一半的患者处于晚期，这限制了治疗前景。除了早期疾病的手术外，几项研究表明，放化疗在壶腹癌的治疗中还具有额外的益处。类似地，化疗在治疗有远处转移/复发的晚期壶腹癌中起着至关重要的作用。尽管疾病的分期、淋巴结状况和组织形态学是三个关键的预后变量，但最近人们对壶腹癌的遗传景观给予了极大的关注。在这篇综述中，我们讨论了各种描述放化疗和化疗在早期和晚期壶腹癌治疗中的作用的研究。此外，我们还总结了壶腹癌的分子结构和新的治疗策略，这些策略可能针对涉及肿瘤细胞的基因改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.